UBS Group
BCAB icon

UBS Group’s BioAtla BCAB Stock Holding History

UBS Group’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$60.5K Buy
7,511
+2,997
+66% +$35.1K ﹤0.01% 7265
2025
Q4 		$128K Buy
4,514
+2,779
+160% +$109K ﹤0.01% 6783
2025
Q3 		$59.7K Buy
1,735
+1,143
+193% +$26.4K ﹤0.01% 7442
2025
Q2 		$11.7K Sell
592
-375
-39% -$7.6K ﹤0.01% 8773
2025
Q1 		$16.8K Sell
967
-50
-5% -$1.07K ﹤0.01% 8342
2024
Q4 		$30.1K Buy
1,017
+798
+364% +$67K ﹤0.01% 7602
2024
Q3 		$19.3K Sell
219
-349
-61% -$29.3K ﹤0.01% 7396
2024
Q2 		$38.9K Sell
568
-379
-40% -$45.1K ﹤0.01% 6883
2024
Q1 		$163K Sell
947
-9
-0.9% -$1.12K ﹤0.01% 5981
2023
Q4 		$118K Buy
956
+504
+112% +$43.7K ﹤0.01% 6090
2023
Q3 		$38.5K Sell
452
-40
-8% -$5.1K ﹤0.01% 6461
2023
Q2 		$73.8K Buy
+492
New +$84.6K ﹤0.01% 6230
2023
Q1 		– Sell
-61
Closed -$25.3K – 9603
2022
Q4 		$25.3K Sell
61
-51
-46% -$21.2K ﹤0.01% 7410
2022
Q3 		$43K Buy
+112
New +$36.7K ﹤0.01% 6492
2022
Q1 		– Sell
-1,420
Closed -$1.39M – 10249
2021
Q4 		$1.39M Buy
1,420
+629
+80% +$805K ﹤0.01% 4079
2021
Q3 		$1.16M Buy
791
+746
+1,658% +$1.45M ﹤0.01% 4057
2021
Q2 		$96K Sell
45
-6
-12% -$13.6K ﹤0.01% 5909
2021
Q1 		$129K Buy
51
+41
+410% +$105K ﹤0.01% 5758
2020
Q4 		$17K Buy
+10
New +$16.7K ﹤0.01% 7049

Other funds holding BCAB

ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

UBS Group's BCAB Position: Q1 2026 in Review

UBS Group increased its BioAtla (BCAB) stake by 66% in Q1 2026, buying an estimated $35.1K and bringing the position to 7,511 shares worth $60.5K. The position accounts for ﹤0.01% of the portfolio, ranked #7265.

UBS Group first reported a position in BCAB in Q4 2020 and has held it in 19 quarters since. The position peaked at $1.39M in Q4 2021. 36 funds tracked by Wall St. Rank hold BCAB as of Q1 2026.

  • UBS Group held 7,511 shares of BioAtla worth $60.5K as of Q1 2026.
  • UBS Group bought 2,997 BioAtla shares in Q1 2026, an estimated $35.1K.
  • BioAtla made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7265 holding.
  • UBS Group first reported a position in BioAtla in Q4 2020 and has held it in 19 quarters since.
  • UBS Group's BioAtla position peaked at $1.39M in Q4 2021.
  • 36 funds tracked by Wall St. Rank held BioAtla as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.